About Indapta
Indapta is a company based in Seattle (United States) founded in 2016. Indapta has raised $72.5 million across 3 funding rounds from investors including HHS, RA Capital and Leaps by Bayer. Indapta offers products and services including G-NK Cell Therapy. Indapta operates in a competitive market with competitors including Novartis, Catalent, Surrozen, Biotage and Curia, among others.
- Headquarter Seattle, United States
- SectorsHealthcare
- Website indapta.com
- Total Equity Funding$72.5M (USD)
in 3 rounds
- Latest Funding Round$22.5M (USD), Series A
Dec 2024
- InvestorsHHS
& 5 more
Products & Services of Indapta
Indapta offers a comprehensive portfolio of products and services, including G-NK Cell Therapy.
Allogeneic therapy targeting cancer and autoimmune diseases via NK cells
Funding Insights of Indapta
Indapta has successfully raised a total of $72.5M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $22.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $72.5M
- Total Rounds 3
- Last Round Series A — $22.5M
- First Round $300,000
(May 2019)
- Investors Count 6
All 3 funding rounds of Indapta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $22.5M | Series A | – | – | |
| Feb 2022 | $50M | Series A | – | RA Capital Management | |
| May 2019 | $300,000 | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Indapta
Indapta has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, RA Capital and Leaps by Bayer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life sciences sector | – | leaps.bayer.com | Leverkusen, Germany | |
- | – | vertexventureshc.com | - | |
Pontifax Venture Capital is focused on life sciences investments. | – | pontifax.com | Herzeliya, Israel | |
A venture philanthropy fund focused on myeloma cure acceleration is operated. | 2019 | myelomainvestmentfund.org | Norwalk, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Indapta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Indapta
17 people are tracked at Indapta (6 in leadership, 11 in board & advisors).
| Name | Role | Group |
|---|---|---|
Neil Sankar | Senior Medical Director and Medical Monitor | Leadership |
Robert Sikorski | Acting Chief Medical Officer | Leadership |
Mark W. Frohlich | CEO | Leadership |
Matthew C. | Director, Preclinical And Translational Research | Leadership |
Austin Bigley | VP, Research | Leadership |
Stefanie Mandl-Cashman | Acting Chief Scientific Officer | Leadership |
Vaughn Smider | Advisor | Board & advisors |
Sungjin Kim | Advisor | Board & advisors |
Ronald Martell | Executive Chairman & Co-Founder | Board & advisors |
Nina Shah | Advisor | Board & advisors |
Todd A. Fehniger | Advisor | Board & advisors |
John Sunwoo | Advisor | Board & advisors |
Fabio Pucci | Director | Board & advisors |
Lori Hu | Director | Board & advisors |
Laura Stoppel | Director | Board & advisors |
Jim Weiss | Director | Board & advisors |
Ran Nussbaum | Director | Board & advisors |
Complete people profiles for Indapta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Indapta
3 dated milestones of Indapta across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Indapta is founded.
- Funding First funding round of $300K.
- Funding Latest funding round, Series A, of $22.5M.
Competitors of Indapta
Indapta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Novartis, Catalent, Surrozen, Biotage and Curia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novartis.com | 1996 | Basel, Switzerland | – | 97 | R&D focused on manufacturing of drugs for multiple therapeutic areas | |
| catalent.com | 2007 | Somerset, United States | – | 9,390 | CDMO offering drug and biologics development services | |
| surrozen.com | 2016 | San Francisco, United States | $133M | 80 | Selective Wnt agonists are developed for human tissue regeneration. | |
| biotage.com | 2009 | Uppsala, Sweden | – | – | Organic synthesis, analytical, and peptide chemistry services for drug discovery and development | |
| curiaglobal.com | 1991 | Albany, United States | – | 1,918 | Drug research, development, testing, and consulting services are provided. | |
| amplify-bio.com | 2021 | Hilliard, United States | $229.75M | – | Provides contract research, development, and manufacturing services for biologic drugs. | |
| wuxibiologics.com | 2008 | Shanghai, China | – | 257 | Protein therapeutics are developed and manufactured by WuXi Biologics. | |
| tirupatigroup.co.in | 1980 | Paonta Sahib, India | $51.55M | 1,827 | Pharmaceutical products are manufactured under contract by Tirupati Medicare. |
Detailed competitors of Indapta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Indapta
Complete news archive for Indapta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Indapta
10 companies that operate in the same segment as Indapta (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Indapta
Indapta was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Indapta is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Indapta is a funded company, having raised a total of $72.5M across 3 funding rounds to date. The company's 1st funding round was a Grant of $300K, raised on May 2019.
Indapta, established in 2016, excels in providing healthcare solutions, biopharma outsourcing, diversified, and biologics. Limited information available. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide. It continues to evolve, meeting industry challenges with strategic approaches.
Indapta offers G-NK Cell Therapy.
Indapta has 6 investors. Key investors include HHS, RA Capital, Leaps by Bayer, Vertex Ventures HC, and Pontifax Venture Capital.